You are viewing an incomplete version of our website. Please click to reload the website as full version.

anti-Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antibodies

CDKN2A generates several transcript variants which differ in their first exons.

list all antibodies Gene Name GeneID UniProt
Anti-Rat CDKN2A CDKN2A 25163 Q9R0Z3
Anti-Human CDKN2A CDKN2A 1029 P42771,Q8N726
Anti-Mouse CDKN2A CDKN2A 12578 P51480,Q64364
How to order from antibodies-online
  • +1 877 302 8632
  • +1 888 205 9894 (toll-free)
  • Order online
  • orders@antibodies-online.com

More Antibodies against Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) Interaction Partners

Human Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. p16INK4a mRNA levels in T-lymphocytes were significantly correlated with chronologic age in older adults undergoing coronary artery bypass grafting, but levels did not predict any adverse outcomes.

  2. The CDKN2A/CDKN2B (show CDKN2B Antibodies) rs4977756 polymorphism increases the risk of developing glioma in Caucasians. (Meta-analysis)

  3. Data indicate that Philadelphia chromosome-positive (Ph-positive) acute lymphoblastic leukemia (ALL) patients who presented with cyclin dependent kinase inhibitor 2A/B (CDKN2A/B) deletion showed a higher rate of CD20 antigen (show MS4A1 Antibodies) expression.

  4. These results indicate that the inhibitory effect of rapamycin may be due mainly to increased p14 (show S100A9 Antibodies), p15 (show CDKN2B Antibodies), and p57 (show CDKN1C Antibodies) expression via promoter demethylation and decreased mTOR (show FRAP1 Antibodies) and p70S6K (show RPS6KB1 Antibodies) expression in ALL cell lines.

  5. homozygous deletions in CDKN2A and hemizygous loss of NF2 (show NF2 Antibodies) as detected by fluorescence in situ hybridization would confer a poor clinical outcome and may guide future treatment decisions for patients with peritoneal mesothelioma.

  6. Findings of frequent mutations in CDKN2A, NOTCH1 (show NOTCH1 Antibodies), PIK3CA (show PIK3CA Antibodies), and EGFR (show EGFR Antibodies) (all in excess (show RCC1 Antibodies) of 20%) point to potential therapeutic avenues. Trials of targeted therapies directed toward these mutations should be explored.

  7. identify high copy number gain of MCL1 (show MCL1 Antibodies) (chromosome 1q) and loss of CDKN2A (P16, chromosome 9p) in metastatic BRAF (show BRAF Antibodies)

  8. This barrier is overcome by spontaneous methylation of the p16 (INK4a) promoter, allowing the proliferation of cells with telomere dysfunction and ensuing chromosome instability.

  9. Authors review how NOTCH1 (show NOTCH1 Antibodies) and p16 contribute in head and neck cancer development and how microRNAs quantitatively control their xpression. [Review]

  10. Gene expression of MYCN (show MYCN Antibodies), HMGA2, CDKN2A and DICER1 (show DICER1 Antibodies) were investigated with RT-qPCR in surgically resected NSCLC tumour tissue from 175 patients

Mouse (Murine) Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) interaction partners

  1. AMPKalpha2 (show PRKAA2 Antibodies) isoform plays a fundamental role in anti-oxidant stress and anti-senescence

  2. that MEK (show MDK Antibodies) activity induced cell cycle arrest through accumulation of p16/19(cdkn2a)

  3. Data indicate the cyclin-dependent kinase inhibitor 2A (p19Arf) and interferon beta (IFN-beta (show IFNB1 Antibodies)) combination as a cancer immunotherapy strategy.

  4. Our findings reveal a novel role for p16(Ink4a) and cellular senescence in promoting insulin (show INS Antibodies) secretion by beta cells and in regulating normal functional tissue maturation with age.

  5. Loss of Nf2 (show NF2 Antibodies) and Cdkn2a/b have synergistic effects with PDGF-B (show PDGFB Antibodies) overexpression promoting meningioma malignant transformation.

  6. Inactivation of INK4a and ARF induces myocardial proliferation and improves cardiac repair following ischemiareperfusion

  7. loss of p19ARF overcomes senescence of LSECs, allowing immortalization of cells without losing endothelial characteristics.

  8. Increased gene dosage of Ink4a, Arf1 (show ARF1 Antibodies) and p53 (show TP53 Antibodies) delays age-associated central nervous system functional decline.

  9. Dysregulation of the Bmi-1 (show BMI1 Antibodies)/p16Ink4a pathway provokes an aging-associated decline of submandibular gland function.

  10. Results show that epigenetic silencing of p16(Ink4a) in selected liver cells bypassing senescence is a general principle for development of liver tumors with beta-catenin (show CTNNB1 Antibodies) involvement in mice independent of the initial stimulus.

Cyclin-Dependent Kinase Inhibitor 2A (Melanoma, P16, Inhibits CDK4) (CDKN2A) Antigen Profile

Protein Summary

This gene generates several transcript variants which differ in their first exons. At least three alternatively spliced variants encoding distinct proteins have been reported, two of which encode structurally related isoforms known to function as inhibitors of CDK4 kinase. The remaining transcript includes an alternate first exon located 20 Kb upstream of the remainder of the gene\; this transcript contains an alternate open reading frame (ARF) that specifies a protein which is structurally unrelated to the products of the other variants. This ARF product functions as a stabilizer of the tumor suppressor protein p53 as it can interact with, and sequester, the E3 ubiquitin-protein ligase MDM2, a protein responsible for the degradation of p53. In spite of the structural and functional differences, the CDK inhibitor isoforms and the ARF product encoded by this gene, through the regulatory roles of CDK4 and p53 in cell cycle G1 progression, share a common functionality in cell cycle G1 control. This gene is frequently mutated or deleted in a wide variety of tumors, and is known to be an important tumor suppressor gene.

Gene names and symbols associated with CDKN2A

  • cyclin-dependent kinase inhibitor 2A (Cdkn2a) antibody
  • cyclin-dependent kinase inhibitor 2A (LOC100340625) antibody
  • cyclin-dependent kinase inhibitor 2A (CDKN2A) antibody
  • ARF antibody
  • ARF-INK4a antibody
  • CDK4I antibody
  • CDKN2 antibody
  • CMM2 antibody
  • INK4 antibody
  • INK4A antibody
  • INK4a-ARF antibody
  • Ink4a/Arf antibody
  • MLM antibody
  • MTS-1 antibody
  • MTS1 antibody
  • P14 antibody
  • P14ARF antibody
  • P16 antibody
  • p16(INK4a) antibody
  • P16-INK4A antibody
  • p16Cdkn2a antibody
  • P16INK4 antibody
  • p16INK4a antibody
  • P19 antibody
  • p19 antibody
  • P19ARF antibody
  • Pctr1 antibody
  • TP16 antibody

Protein level used designations for CDKN2A

CDK4I , Cyclin dependent kinase inhibitor 2A (p16, inhibits CDK4) , cell cycle inhibitor , cell cycle regulator , cyclin-dependent kinase 4 inhibitor A , cyclin-dependent kinase inhibitor 2a p16Ink4a , cyclin-dependent kinase inhibitor 2a p19Arf , p16-INK4 , p16-INK4a , CDK4 inhibitor p16-INK4 , cell cycle negative regulator beta , cyclin-dependent kinase inhibitor 2A (melanoma, p16, inhibits CDK4) , multiple tumor suppressor 1 , cyclin-dependent kinase inhibitor 2A (p16, inhibits CDK4) , cyclin-dependent kinase inhibitor 2A, isoforms 1/2 , cyclin-dependent kinase inhibitor protein , mitochondrial smARF

GENE ID SPECIES
25163 Rattus norvegicus
100731972 Cavia porcellus
100340625 Oryctolagus cuniculus
1029 Homo sapiens
12578 Mus musculus
Did you look for something else?